Defining patient groups for immunotherapy
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Bristol might play a role in front-line lung cancer after all | Evaluate
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Checkpoint inhibition in non-small-cell lung cancer: expanding the range of options - memoinOncology
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial - The Lancet
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Forest plots for (a) overall survival and (b) progression-free survival... | Download Scientific Diagram
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
Overall survival in the Asian subpopulation, including Japanese... | Download Scientific Diagram
US regulator scoops Asco with Bristol's lung cancer approval | Evaluate
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 | Journal for ImmunoTherapy of Cancer
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
